EUCTR2006-004176-13-DE进行中（未招募）不适用
A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-week Study to Investigate the Safety and Efficacy of Oral SPP635 450 mg Once Daily in Patients With Mild to Moderate Hypertension
Speedel Pharma Ltd.0 个研究点开始时间: 2007年1月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with mild to moderate hypertension with blood pressures between 140 and 179 mmHg systolic, and 109 mmHg diastolic blood pressure (office blood pressure)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Women of childbearing potential
- •pregnant and lactating women
- •any current or past heart disease
- •any history of kidney failure
- •any history of diabetes mellitus
- •HbA1c > 6%
研究者
相似试验
进行中（未招募）
不适用
A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Fourfold Cross-Over Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects with Type 2 Diabetes Mellitus (T2DM) after an Oral Glucose Tolerance TestEUCTR2011-002986-39-DEProfil Institut für Stoffwechselforschung GmbH
进行中（未招募）
1 期
A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.Dental anxietyEUCTR2006-003912-23-GBAddex Pharmaceuticals SA50
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with severe acute myocardial infarction.Treatment of ST-elevated myocardial infarction (STEMI) after percutaneous intervention (PCI)MedDRA version: 20.0 Level: SOC Classification code 10007541 Term: Cardiac disorders System Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0 Level: LLT Classification code 10064346 Term: STEMI System Organ Class: 10007541 - Cardiac disordersEUCTR2018-003676-12-SEAthera Biotechnologies AB80
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with severe acute myocardial infarction.Treatment of ST-elevated myocardial infarction (STEMI) after percutaneous intervention (PCI)MedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10064346Term: STEMISystem Organ Class: 10007541 - Cardiac disordersEUCTR2018-003676-12-NLAthera Biotechnologies AB80
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with low artery flow despite percutan coronar intervention (PCI) for acute myocardial infarction.EUCTR2018-003676-12-DKAthera Biotechnologies AB80